Researchers suggest in a new study from Johns Hopkins School of Medicine that a new blood test can help physicians identify traumatic brain injury (TBI) patients who may need extra therapy or experimental treatments.

The study was published recently in the Journal of Neurotrauma, according to a news release from Johns Hopkins Medicine.

Until recently, the release notes, most physicians have relied on CT scans and patients’ symptoms to determine whether to send them home and have them resume their usual activities or take extra precautions. However, CT scans can only detect bleeding in the brain, not damage to brain cells, which can happen without bleeding.

“A typical situation is that someone comes to the emergency department with a suspected TBI, we get a CT scan, and if the scan shows no bleeding, we send the patient home,” says Frederick Korley, MD., PhD, an assistant professor of emergency medicine at the Johns Hopkins University School of Medicine and the study’s first author, in the release.

“However, these patients go home and continue having headaches, difficulty concentrating and memory problems, and they can’t figure out why they are having these symptoms after doctors told them everything was fine,” he continues.

Korley and the rest of the research team wanted to know if a blood test could better predict which patients would have ongoing brain injury-related problems, to provide better treatment for them. So they measured the levels of three proteins that they suspected play a role in brain cell activity in more than 300 patients with a TBI and 150 patients without one. Then, they followed those with a TBI for the next 6 months, the release explains.

Levels of one protein, called brain-derived neurotrophic factor (BDNF), taken within 24 hours of TBI occurrence, could predict its severity and how a patient would fare, they found. While healthy people averaged 60 nanograms per milliliter of BDNF in their bloodstreams, patients with brain injuries had less than one-third of that amount, averaging less than 20 nanograms per milliliter, and those with the most severe TBIs had even lower levels, around 4 nanograms per milliliter.

Moreover, patients with high levels of BDNF had mostly recovered from their injuries 6 months later. But in patients with the lowest levels of BDNF, symptoms still lingered at follow-up. The results suggest that a test for BDNF levels, administered in the emergency department, could help stratify patients, the release continues.

“The advantage of being able to predict prognosis early on is that you can advise patients on what to do, recommend whether they need to take time off work or school, and decide whether they need to follow up with a rehab doctor or neurologist,” Korley says in the release.

In addition, the release notes, it could help decide which patients to enroll in clinical trials for new drugs or therapies targeting severe TBIs.

Korley states in the release that he would like to follow up with more research on why, at a molecular level, brain injuries lower levels of BDNF in the blood and whether things known to increase BDNF levels—including exercise and omega-3 fatty acids—could help treat TBIs.

He also would like to know whether changes in BDNF levels over time can be a proxy for recovery and if they could be used to gauge the effectiveness of an intervention, per the release.

“We looked at that very first blood sample obtained within 24 hours of an injury,” he says in the release. “But for BDNF to be used as a surrogate outcome, we’ll have to see what happens to BDNF blood levels down the line, at 1, 3, or 6 months after the injury,” he continues.

[Source(s): Johns Hopkins Medicine, Science Daily]